ecancer

ASCEND-5: Ceritinib for ALK positive NSCLC previously treated with crizotinib

Dr Giorgio Scagliotti - University of Turin, Turin, Italy

9 Oct 2016

Pembrolizumab 'should be first line treatment' for high PD1 expressing NSCLC patients

Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany

9 Oct 2016

Firstline pembrolizumab plus chemo improves NSCLC outcomes

Dr Corey Langer - University of Pennsylvania, Philadelphia, USA

9 Oct 2016

Immunotherapy and treatment advances in small cell lung cancer

Prof Dean Fennell - University of Leicester, Leicester, UK

6 Oct 2016

Lung cancer screening in the UK

Prof John Field - University of Liverpool, Liverpool, UK

6 Oct 2016

Screening, surgical cure and new developments: Future smart surgical approaches for brain mets

Dr Francesco Di Meco - Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

6 Oct 2016

ALK mutations in paediatric tumours

Dr Suzanne Turner - Cambridge University, Cambridge, UK

5 Oct 2016

NSCLC biology and new therapies: Immunotherapies

Dr Rafael Rosell - Catalan Institute of Oncology, Barcelona, Spain

5 Oct 2016

NSCLC biology and new therapies: Reversing resistance

Prof Michael Seckl - Imperial College London, London, UK

5 Oct 2016

Screening, surgical cure and new developments: Current state of the art surgery

Dr Ugo Pastorino - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

5 Oct 2016

Screening, surgical cure and new developments: Q & A

Dr Henschke, Prof Field, Dr Pastorino, Dr Di Meco

5 Oct 2016

NSCLC biology and new therapies: Animal models of lung cancer

Prof Julian Downward - The Francis Crick Institute, London, UK

5 Oct 2016

More from ecancer